Johnson & Johnson (JNJ) Stock Forecast, Price Target & Predictions
JNJ Stock Forecast
Johnson & Johnson stock forecast is as follows: an average price target of $176.29 (represents a 7.21% upside from JNJ’s last price of $164.44) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.
JNJ Price Target
The average price target for Johnson & Johnson (JNJ) is $176.29 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $205.00 to $150.00. This represents a potential 7.21% upside from JNJ's last price of $164.44.
JNJ Analyst Ratings
According to 20 Wall Street analysts, Johnson & Johnson's rating consensus is 'Buy'. The analyst rating breakdown for JNJ stock is 0 'Strong Buy' (0.00%), 12 'Buy' (60.00%), 8 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Johnson & Johnson Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 23, 2024 | Narumi Nakagiri | Johnson Rice | $150.00 | $154.24 | -2.75% | -8.78% |
| Jul 17, 2024 | Rick Wise | Stifel Nicolaus | $160.00 | $157.16 | 1.81% | -2.70% |
| May 30, 2024 | Chris Shibutani | Johnson Rice | $160.00 | $144.44 | 10.77% | -2.70% |
| May 30, 2024 | Chris Shibutani | Goldman Sachs | $160.00 | $144.41 | 10.79% | -2.70% |
| May 22, 2024 | Danielle Antalffy | UBS | $180.00 | $152.34 | 18.16% | 9.46% |
| Apr 18, 2024 | Morten Herholdt | Johnson Rice | $170.00 | $145.08 | 17.18% | 3.38% |
| Apr 17, 2024 | Louise Chen | Johnson Rice | $215.00 | $144.32 | 48.97% | 30.75% |
| Apr 17, 2024 | Shagun Singh | RBC Capital | $175.00 | $144.45 | 21.15% | 6.42% |
| Apr 16, 2024 | Rick Wise | Stifel Nicolaus | $155.00 | $144.45 | 7.30% | -5.74% |
| Mar 27, 2024 | Terence Flynn | Morgan Stanley | $169.00 | $155.77 | 8.49% | 2.77% |
The latest Johnson & Johnson stock forecast, released on Jul 23, 2024 by Narumi Nakagiri from Johnson Rice, set a price target of $150.00, which represents a -2.75% decrease from the stock price at the time of the forecast ($154.24), and a -8.78% decrease from JNJ last price ($164.44).
Johnson & Johnson Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 14 |
| Avg Price Target | - | $155.00 | $165.71 |
| Last Closing Price | $164.44 | $164.44 | $164.44 |
| Upside/Downside | -100.00% | -5.74% | 0.77% |
In the current month, the average price target of Johnson & Johnson stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Johnson & Johnson's last price of $164.44. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | Johnson Rice | Overweight | Overweight | Hold |
| Sep 06, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Sep 06, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Sep 03, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 30, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 23, 2024 | Johnson Rice | Overweight | Neutral | Downgrade |
| Jul 18, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 17, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 09, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
Johnson & Johnson's last stock rating was published by Johnson Rice on Sep 06, 2024. The company gave JNJ a "Overweight" rating, the same as its previous rate.
Johnson & Johnson Financial Forecast
Johnson & Johnson Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $23.71B | $21.35B | $25.53B | $24.75B | $24.80B | $23.79B | - | $23.43B | $22.48B | $23.34B | $23.31B | $22.32B | - | $21.08B | $18.34B | $20.69B | $20.75B | $20.73B |
| Avg Forecast | $26.46B | $24.14B | $23.65B | $22.61B | $23.50B | $22.86B | $22.90B | $22.05B | $22.46B | $22.13B | $22.33B | $21.40B | $21.02B | $21.04B | $24.63B | $23.60B | $23.88B | $23.36B | $23.77B | $23.62B | $25.28B | $23.64B | $22.49B | $21.98B | $21.66B | $20.20B | $17.61B | $19.73B | $20.80B | $20.08B |
| High Forecast | $26.70B | $24.36B | $23.86B | $22.81B | $23.71B | $23.07B | $23.10B | $22.25B | $22.67B | $22.28B | $22.53B | $21.60B | $21.06B | $21.23B | $24.86B | $23.81B | $24.10B | $23.57B | $23.77B | $23.92B | $25.60B | $23.94B | $22.78B | $22.26B | $21.94B | $20.46B | $17.83B | $19.98B | $21.06B | $20.34B |
| Low Forecast | $26.19B | $23.90B | $23.40B | $22.38B | $23.26B | $22.63B | $22.66B | $21.82B | $22.24B | $21.89B | $22.10B | $21.18B | $21.01B | $20.82B | $24.38B | $23.36B | $23.64B | $23.12B | $23.77B | $23.33B | $24.96B | $23.34B | $22.21B | $21.71B | $21.39B | $19.95B | $17.39B | $19.49B | $20.54B | $19.83B |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.13% | 1.01% | 1.04% | 1.05% | 1.04% | 1.02% | - | 0.99% | 0.89% | 0.99% | 1.04% | 1.02% | - | 1.04% | 1.04% | 1.05% | 1.00% | 1.03% |
Johnson & Johnson's average Quarter revenue forecast for Mar 24 based on 4 analysts is $21.40B, with a low forecast of $21.18B, and a high forecast of $21.60B. JNJ's average Quarter revenue forecast represents a -9.72% decrease compared to the company's last Quarter revenue of $23.71B (Dec 23).
Johnson & Johnson EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.50B | $6.26B | $6.97B | $6.73B | $6.74B | $6.38B | - | $7.11B | $3.67B | $5.68B | $8.54B | $9.39B | - | $6.26B | $5.71B | $8.58B | $6.12B | $3.42B |
| Avg Forecast | $7.34B | $6.70B | $6.56B | $6.27B | $6.52B | $6.35B | $6.35B | $6.12B | $6.23B | $6.14B | $6.20B | $10.68B | $5.83B | $5.84B | $6.84B | $9.71B | $6.63B | $6.74B | $6.60B | $8.83B | $7.36B | $6.12B | $5.57B | $8.02B | $6.69B | $5.57B | $5.06B | $7.29B | $6.09B | $3.23B |
| High Forecast | $7.41B | $6.76B | $6.62B | $6.33B | $6.58B | $6.40B | $6.41B | $6.17B | $6.29B | $6.18B | $6.25B | $12.81B | $5.84B | $5.89B | $6.90B | $11.65B | $6.69B | $8.08B | $6.60B | $10.59B | $8.84B | $7.35B | $6.68B | $9.63B | $8.03B | $6.68B | $6.08B | $8.75B | $7.30B | $3.88B |
| Low Forecast | $7.27B | $6.63B | $6.50B | $6.21B | $6.45B | $6.28B | $6.29B | $6.06B | $6.17B | $6.08B | $6.13B | $8.54B | $5.83B | $5.78B | $6.77B | $7.77B | $6.56B | $5.39B | $6.60B | $7.06B | $5.89B | $4.90B | $4.46B | $6.42B | $5.36B | $4.45B | $4.05B | $5.84B | $4.87B | $2.59B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.07% | 1.02% | 0.69% | 1.02% | 0.95% | - | 0.81% | 0.50% | 0.93% | 1.53% | 1.17% | - | 1.13% | 1.13% | 1.18% | 1.01% | 1.06% |
4 analysts predict JNJ's average Quarter EBITDA for Mar 24 to be $10.68B, with a high of $12.81B and a low of $8.54B. This is 94.20% upper than Johnson & Johnson's previous annual EBITDA (Dec 23) of $5.50B.
Johnson & Johnson Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $3.52B | $26.03B | $5.14B | $-68.00M | $4.74B | $4.46B | - | $5.15B | $1.74B | $3.67B | $6.28B | $6.20B | - | $3.55B | $3.63B | $5.80B | $4.01B | $1.75B |
| Avg Forecast | $7.97B | $6.87B | $6.86B | $6.50B | $6.40B | $6.60B | $6.66B | $6.49B | $5.57B | $5.27B | $6.57B | $7.21B | $5.52B | $6.09B | $6.34B | $6.56B | $5.42B | $3.82B | $6.17B | $5.96B | $4.83B | $3.48B | $3.54B | $5.42B | $4.39B | $3.16B | $3.22B | $4.93B | $3.99B | $1.66B |
| High Forecast | $8.07B | $6.95B | $6.94B | $6.58B | $6.48B | $6.67B | $6.74B | $6.56B | $5.64B | $5.66B | $6.64B | $8.66B | $5.60B | $6.17B | $6.41B | $7.87B | $5.48B | $4.59B | $6.17B | $7.15B | $5.79B | $4.17B | $4.24B | $6.50B | $5.26B | $3.79B | $3.86B | $5.91B | $4.79B | $1.99B |
| Low Forecast | $7.87B | $6.78B | $6.77B | $6.41B | $6.32B | $6.51B | $6.57B | $6.40B | $5.50B | $4.86B | $6.48B | $5.77B | $5.48B | $6.01B | $6.25B | $5.25B | $5.35B | $3.06B | $6.17B | $4.77B | $3.86B | $2.78B | $2.83B | $4.34B | $3.51B | $2.53B | $2.57B | $3.94B | $3.19B | $1.33B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 4.27% | 0.81% | -0.01% | 0.87% | 1.17% | - | 0.86% | 0.36% | 1.06% | 1.78% | 1.14% | - | 1.13% | 1.13% | 1.18% | 1.01% | 1.06% |
Johnson & Johnson's average Quarter net income forecast for Mar 24 is $7.21B, with a range of $5.77B to $8.66B. JNJ's average Quarter net income forecast represents a 104.92% increase compared to the company's last Quarter net income of $3.52B (Dec 23).
Johnson & Johnson SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $6.51B | $5.40B | $6.67B | $6.14B | $7.15B | $6.09B | - | $5.94B | $6.46B | $6.00B | $6.07B | $5.43B | - | $5.43B | $4.99B | $5.20B | $6.04B | $5.37B |
| Avg Forecast | $6.95B | $6.35B | $6.21B | $5.94B | $6.18B | $6.01B | $6.02B | $5.79B | $5.90B | $5.82B | $5.87B | $6.48B | $5.52B | $5.53B | $6.47B | $5.89B | $6.28B | $5.84B | $6.25B | $5.35B | $7.27B | $5.31B | $4.87B | $4.86B | $6.61B | $4.83B | $4.43B | $4.42B | $6.01B | $5.08B |
| High Forecast | $7.02B | $6.40B | $6.27B | $6.00B | $6.23B | $6.06B | $6.07B | $5.85B | $5.96B | $5.86B | $5.92B | $7.77B | $5.54B | $5.58B | $6.53B | $7.06B | $6.33B | $7.01B | $6.25B | $6.42B | $8.72B | $6.37B | $5.84B | $5.84B | $7.93B | $5.79B | $5.31B | $5.31B | $7.21B | $6.10B |
| Low Forecast | $6.88B | $6.28B | $6.15B | $5.88B | $6.11B | $5.95B | $5.96B | $5.74B | $5.84B | $5.75B | $5.81B | $5.18B | $5.52B | $5.47B | $6.41B | $4.71B | $6.21B | $4.67B | $6.25B | $4.28B | $5.81B | $4.25B | $3.90B | $3.89B | $5.29B | $3.86B | $3.54B | $3.54B | $4.81B | $4.06B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.18% | 0.98% | 1.03% | 1.04% | 1.14% | 1.04% | - | 1.11% | 0.89% | 1.13% | 1.25% | 1.12% | - | 1.13% | 1.13% | 1.18% | 1.01% | 1.06% |
Johnson & Johnson's average Quarter SG&A projection for Mar 24 is $6.48B, based on 4 Wall Street analysts, with a range of $5.18B to $7.77B. The forecast indicates a -0.57% fall compared to JNJ last annual SG&A of $6.51B (Dec 23).
Johnson & Johnson EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.35 | $10.81 | $1.98 | $-0.03 | $1.80 | $1.70 | - | $1.96 | $0.66 | $1.39 | $2.38 | $2.35 | - | $1.35 | $1.38 | $2.20 | $1.52 | $0.67 |
| Avg Forecast | $3.29 | $2.84 | $2.83 | $2.68 | $2.64 | $2.72 | $2.75 | $2.68 | $2.30 | $2.18 | $2.71 | $2.66 | $2.28 | $2.52 | $2.62 | $2.50 | $2.24 | $2.48 | $2.54 | $2.59 | $2.12 | $2.35 | $2.29 | $2.34 | $1.82 | $1.98 | $1.49 | $2.02 | $1.87 | $2.01 |
| High Forecast | $3.33 | $2.87 | $2.87 | $2.71 | $2.68 | $2.76 | $2.78 | $2.71 | $2.33 | $2.34 | $2.74 | $2.69 | $2.31 | $2.55 | $2.65 | $2.53 | $2.26 | $2.51 | $2.54 | $2.63 | $2.15 | $2.39 | $2.33 | $2.38 | $1.85 | $2.01 | $1.52 | $2.05 | $1.90 | $2.04 |
| Low Forecast | $3.25 | $2.80 | $2.80 | $2.65 | $2.61 | $2.69 | $2.71 | $2.64 | $2.27 | $2.01 | $2.68 | $2.62 | $2.26 | $2.48 | $2.58 | $2.47 | $2.21 | $2.44 | $2.54 | $2.54 | $2.08 | $2.31 | $2.25 | $2.30 | $1.79 | $1.94 | $1.47 | $1.98 | $1.84 | $1.98 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 4.30% | 0.76% | -0.01% | 0.80% | 0.69% | - | 0.76% | 0.31% | 0.59% | 1.04% | 1.01% | - | 0.68% | 0.92% | 1.09% | 0.82% | 0.33% |
According to 4 Wall Street analysts, Johnson & Johnson's projected average Quarter EPS for Mar 24 is $2.66, with a low estimate of $2.62 and a high estimate of $2.69. This represents a 96.72% increase compared to JNJ previous annual EPS of $1.35 (Dec 23).
Johnson & Johnson Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $28.56 | $46.29 | 62.08% | Hold |
| BMY | Bristol-Myers Squibb Company | $48.70 | $65.43 | 34.35% | Hold |
| MRK | Merck | $117.84 | $127.74 | 8.40% | Buy |
| JNJ | Johnson & Johnson | $164.38 | $176.29 | 7.25% | Buy |
| GILD | Gilead Sciences | $78.72 | $81.27 | 3.24% | Buy |
| AMGN | Amgen | $320.56 | $286.95 | -10.48% | Buy |
| ABBV | AbbVie | $193.40 | $167.54 | -13.37% | Buy |
| LLY | Eli Lilly and Company | $902.71 | $734.40 | -18.64% | Buy |
JNJ Forecast FAQ
Is Johnson & Johnson a good buy?
Yes, according to 20 Wall Street analysts, Johnson & Johnson (JNJ) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 60.00% of JNJ's total ratings.
What is JNJ's price target?
Johnson & Johnson (JNJ) average price target is $176.29 with a range of $150 to $205, implying a 7.21% from its last price of $164.44. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Johnson & Johnson stock go up soon?
According to Wall Street analysts' prediction for JNJ stock, the company can go up by 7.21% (from the last price of $164.44 to the average price target of $176.29), up by 24.67% based on the highest stock price target, and down by -8.78% based on the lowest stock price target.
Can Johnson & Johnson stock reach $200?
JNJ's highest twelve months analyst stock price target of $205 supports the claim that Johnson & Johnson can reach $200 in the near future.
What are Johnson & Johnson's analysts' financial forecasts?
Johnson & Johnson's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $91.3B (high $92.13B, low $90.37B), average EBITDA is $25.34B (high $25.57B, low $25.08B), average net income is $26.15B (high $26.46B, low $25.8B), average SG&A $24B (high $24.21B, low $23.75B), and average EPS is $10.8 (high $10.92, low $10.65). JNJ's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $96.85B (high $97.74B, low $95.87B), average EBITDA is $26.88B (high $27.12B, low $26.61B), average net income is $28.21B (high $28.54B, low $27.83B), average SG&A $25.46B (high $25.69B, low $25.2B), and average EPS is $11.65 (high $11.78, low $11.49).
Did the JNJ's actual financial results beat the analysts' financial forecasts?
Based on Johnson & Johnson's last annual report (Dec 2023), the company's revenue was $94.94B, beating the average analysts forecast of $90.29B by 5.15%. Apple's EBITDA was $24.02B, missing the average prediction of $28.22B by -14.86%. The company's net income was $17.94B, missing the average estimation of $24.51B by -26.81%. Apple's SG&A was $24.76B, beating the average forecast of $23.41B by 5.77%. Lastly, the company's EPS was $6.86, missing the average prediction of $9.92 by -30.82%. In terms of the last quarterly report (Dec 2023), Johnson & Johnson's revenue was $23.71B, beating the average analysts' forecast of $21.02B by 12.77%. The company's EBITDA was $5.5B, missing the average prediction of $5.83B by -5.74%. Johnson & Johnson's net income was $3.52B, missing the average estimation of $5.52B by -36.28%. The company's SG&A was $6.51B, beating the average forecast of $5.52B by 17.87%. Lastly, the company's EPS was $1.35, missing the average prediction of $2.28 by -40.81%